What PE-22-28 is
PE-22-28 is a seven-amino-acid shortened analogue of spadin designed to inhibit the TREK-1 potassium channel. It is an experimental neuroscience compound with no FDA-approved product, psychiatric indication, or human dose.
Antidepressant claims come from mice
Cell experiments found potent TREK-1 inhibition, and mouse behavioral tests reported antidepressant-like effects, neurogenesis markers, and synaptogenesis-related changes.[1] Forced-swim and novelty-suppressed-feeding results are screening signals, not diagnoses or clinical outcomes. Teloryx found no controlled human efficacy, pharmacokinetic, or safety trial.
Human neurologic safety is unknown
TREK-1 participates in neuronal excitability, so mood, seizure, sedation, interaction, and other neurologic effects cannot be predicted from the limited models. Pregnancy, bipolar disorder, suicidality, antidepressant combinations, long-term exposure, and withdrawal have not been characterized.
Regulatory status
PE-22-28 is unapproved in the United States. Compounded drugs are not FDA-approved or premarket-verified for safety, effectiveness, or quality.[2] Teloryx publishes no dose, cycle, or preparation protocol.